Efficacy of cabozantinib (Cabo) in medullary thyroid cancer (MTC) patients with RAS or RET mutations: Results from a phase III study.
Steven I. Sherman
Consultant or Advisory Role - AstraZeneca; Bayer; Eisai; Exelixis
Honoraria - Exelixis
Ezra E.W. Cohen
Consultant or Advisory Role - Boehringer Ingelheim
Honoraria - Biodesix
Patrick Schoffski
Consultant or Advisory Role - Exelixis
Honoraria - Exelixis
Research Funding - Exelixis
Rossella Elisei
Consultant or Advisory Role - Exelixis
Honoraria - Exelixis
Martin Schlumberger
Consultant or Advisory Role - Exelixis (U)
Lori J. Wirth
No relevant relationships to disclose
Milan Mangeshkar
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Dana T. Aftab
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Douglas O. Clary
Employment or Leadership Position - Exelixis
Stock Ownership - Exelixis
Marcia S. Brose
Consultant or Advisory Role - Exelixis
Research Funding - Exelixis